美国BellBrook Labs  
BellBrook Labs自2002年成立以来，一直向制药公司提供高通量筛选工具，以加速有效疗法的开发。在2005年，它开发了Transcreener分析平台，打破了之前束缚药物开发的瓶颈。这个分析平台产生的数据能更好地预测病人对药物的反应，并改进药物靶点测试的企划以及新药治疗的开展。在2007年，BellBrook Labs收购了Salus技术，来开发一种更新颖的技术平台，使筛选实验室能扩大他们的细胞分析能力。通过提供创新的生物化学和细胞生物学技术，BellBrook能够积极应对药物开发中面临的种种挑战。

BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. As a small, R&D-driven company, we identify areas where there is a strong need but a significant technical hurdle, and then we develop a solution. The company is focused on taking creative approaches to new product development and to continually improving the level of service provided to our customers. When you communicate with someone from BellBrook it will be immediately apparent that we share your passion for discovering more effective disease therapies and your respect for the complexity of biology. We have included names of BBL employees and direct phone numbers on this website. Please feel free to contact any of us with questions or suggestions regarding our products and technologies or how we might better serve your needs.

Transcreener® Biochemical Assay Technology: Our proprietary Transcreener® HTS Platform was developed to move more new targets into HTS more rapidly, and to streamline selectivity profiling within a target family. It relies on homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, GDP, AMP and GMP, that are formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases and glycosyltransferases, that catalyze the covalent regulatory reactions that are central to cell signaling. Each Transcreener Assay provides a generic detection method for multiple enzyme families. This means that you can focus on evaluating new therapeutic strategies and optimizing lead molecules rather than on time-consuming assay development for individual targets. Since introduction of the first Transcreener assays in 2005, the platform has been rapidly validated and adopted by pharmaceutical and biotechnology screening labs around the world.

iuvo™ MicroConduit Array Technology: BellBrook is developing microscale cell culture devices with unique advantages for miniaturization and automation of cellular assays. These MicroConduit Arrays rely on liquid displacement from microchannels rather than the cumbersome aspiration and replacement used with open wells, yet they are compatible with existing liquid dispensing equipment. Applications will include invasion and migration assays and reconstruction of cells in complex three dimensional formats that recapitulate paracrine signaling in the context of native tissue.